Modeling serological testing to inform relaxation of social distancing for COVID-19 control

Alicia N. M. Kraay, Kristin N. Nelson, Conan Y. Zhao, David Demory, Joshua S. Weitz & Benjamin A. Lopman

Serological testing remains a passive component of the public health response to the COVID-19 pandemic. Using a transmission model, we examine how serological testing could have enabled seropositive individuals to increase their relative levels of social interaction while offsetting transmission risks. We simulate widespread serological testing in New York City, South Florida, and Washington Puget Sound and assume seropositive individuals partially restore their social contacts. Compared to no intervention, our model suggests that widespread serological testing starting in late 2020 would have averted approximately 3300 deaths in New York City, 1400 deaths in South Florida and 11,000 deaths in Washington State by June 2021. In all sites, serological testing blunted subsequent waves of transmission. Findings demonstrate the potential benefit of widespread serological testing, had it been implemented in the pre-vaccine era, and remain relevant now amid the potential for emergence of new variants.
SARS-CoV-2 emerged in China in late 2019 leading to the COVID-19 pandemic, with over 213 million detected cases and over 4.4 million deaths globally and approximately 38 million detected cases and 643,000 deaths reported in the U.S. as of August 24, 2021. Unprecedented social distancing measures were enacted in early 2020 to reduce transmission and blunt the epidemic peak. In March 2020, U.S. states began to close schools, suspend public gatherings, and encourage employees to work from home if possible. By mid-April, 95% of the U.S. and over 30% of the global population were under some form of shelter-in-place order. Federal social distancing guidelines expired on April 30, 2020; throughout the summer, many state and local governments relaxed stay-at-home orders partially or completely.

Relaxing these social distancing policies resulted in increased community transmission, and case counts increased as states further relaxed restrictions on public gatherings, restaurant dining, and operation of businesses. Behavioral change combined with the accelerated transmission in a largely immunologically naive population resulted in a wave of cases and deaths in the late summer and early Fall 2020. A second, larger wave in the Fall, and then a third wave in the Winter of 2020. During late spring 2021, the widespread availability of SARS-CoV-2 vaccines in the United States coupled with higher levels of natural immunity allowed social distancing interventions to be relaxed further. Despite the widespread availability of vaccines, a fourth wave of cases in the US beginning in late Summer 2021 is due to multiple factors, including fatigue from adhering to strict social distancing measures and heterogeneous vaccine coverage. The rise of more transmissible variants of concern as well as the possibility of variants that escape natural or vaccine-derived immunity continues to require vigilance in the event that COVID-19 incidence increases again. Indeed, this fourth wave reinforces the need to evaluate other measures—including individualized policies based on disease or immune status—as part of integrative response campaigns.

In this paper, we explore how immune shielding could be used to further reduce population risk. A shielding strategy aims to identify and deploy recovered/vaccinated (and likely immune) individuals as focal points for sustaining less risky interactions. This strategy has the objective of sustaining interactions necessary for the functioning of essential services while reducing the risk of exposing individuals who remain susceptible to infection. As the basis for a shielding strategy, widespread serological testing programs have the potential to identify individuals or groups who are likely immune, allowing some individuals to return to activities while keeping deaths and hospital admissions at sufficiently low levels. In this strategy, individuals who test positive would preferentially replace susceptible individuals in close-contact interactions, such that more contacts are between susceptible and immune individuals rather than between susceptible and potentially infectious individuals. Immune shielding may be particularly useful given the high incidence in focal regions resulting from incomplete vaccine coverage and partial levels of population immunity.

Serosurveys of SARS-CoV-2 in the U.S. vary in their estimates of seroprevalence but collectively suggest that infections far outnumber documented cases. To the extent that antibodies serve as a correlate of immunity, serological testing may be used to identify protected individuals. While our understanding of the immunological response to SARS-CoV-2 infection remains incomplete, the vast majority of infected individuals seroconvert, with detectable antibody levels persisting at least several months after infection for the majority of individuals. SARS-CoV-2 reinfecions have been documented but remain relatively rare (though emerging variants of concern have raised questions regarding breakthrough infection rates). Together, these data suggest that recovered individuals have substantial protection against subsequent re-infection. Once identified, antibody test-positive individuals could return to pre-pandemic levels of social interactions and therefore dilute (via shielding) potentially risky interactions between susceptible and infectious individuals—keeping in mind that variants of concern may require that other NPIs are still utilized (e.g., masking in indoor settings).

Such strategies, however, rely on correctly identifying immune individuals. There are currently more than 50 serological assays for the detection of SARS-CoV-2 antibodies that have been authorized for emergency use by the Food and Drug Administration. The performance of these tests varies considerably. For the purpose of informing safe social distancing policies, specificity rather than sensitivity is of primary concern. An imperfectly specific test will result in false positives, leading to individuals being incorrectly classified as immune. If used as a basis to relax social distancing measures, there is concern that this error could heighten the risk for individuals who test positive and lead to an increase in community transmission. For this reason, this paper evaluates the integration of serological testing into a COVID-19 transmission model to evaluate the level of serological testing needed to reduce expected fatalities while increasing the fraction of focal populations who can re-engage in socio-economic activities.

Results

To evaluate the epidemiological consequences of using mass serological testing to inform the relaxation of social distancing measures in the pre-vaccine era, we modeled transmission dynamics and serological testing for SARS-CoV-2 using a deterministic, compartmental SEIR-like model (Fig. 1). Recovered, susceptible, latently infected, and asymptomatic persons test positive at rates that are functions of testing frequency, sensitivity (for recovered individuals), and specificity (for non-immune individuals). We model contacts at home, work, school, and other locations among three age groups: children and young adults (<20 years), working adults (20–64 years), and elderly (65+ years). We used a Markov Chain Monte Carlo (MCMC) approach to fit the model to time series of deaths and cross-sectional seroprevalence data from three U.S. metropolitan areas with distinct COVID-19 epidemic trajectories: the New York City Metro Region, South Florida, and the Washington Puget Sound region, including changes in policy impacting social distancing behaviors, to evaluate an immunological shielding strategy per-region.

Model fits to fatalities and serological data. We explored the impacts of social distancing on epidemic outcomes in the absence of serological testing. To do so, we first used MCMC model-data integration to fit the model to reported deaths and seroprevalence point estimates from each of three metropolitan areas. Model fits reproduced reported death trends reasonably well through June 2020 and seroprevalence estimates early in the outbreak (see Fig. 2 for fits; Supplementary Figs. 1–10 for full model diagnostics). Of note, fits were poorer for New York City, which was not unexpected due to the unique severity of the initial pandemic wave there. Fits were moderately good for Washington Puget Sound and best for South Florida. We note that the probability of infection per contact had narrow credible intervals (CrI), indicating posterior confidence in the ability of the model to uniquely identify parameter sets consistent with key features of infection. Credible intervals were wider for the fraction of infections that were symptomatic and were widest for social distancing parameters, indicating limits of parameter identifiability. Nonetheless,
the consistency of fits across multiply-independently sampled chains implies that the model outcomes early in the epidemic are insensitive to variation in these parameters—enabling us to evaluate baseline predictions with and without serological testing.

**Epidemic dynamics in the absence of serological testing.** In all three sites, our models predicted a second epidemic peak in the fall and winter of 2020–2021, consistent with the qualitative shape of the epidemic trajectory (Fig. 3). For New York, the second peak is predicted to be smaller than the first, whereas the second wave is expected to be larger than the first wave in Washington and South Florida. If social distancing was sustained at Fall 2020 levels without any further interventions, our model predicts that 46–55% of the population across the three metropolitan areas (55% in New York City, 95% credible interval (CI): 27–69%; 46% in South Florida, 95% CI: 31–60%; and 46% in Washington, 95% CI: 2–55%) would be infected with SARS-CoV-2 by June 2021, resulting in 72,000 cumulative deaths across the three sites (43,000 deaths in New York City, 95% CI: 21,000–64,000; 10,000 deaths in South Florida, 95% CI: 6000–17,000; and 19,000 deaths in Washington, 95% CI: 1000–32,000) since the start of the pandemic (Fig. 4, top row). In reality, the death count for all three locations was 50,272 (34,492 in New York City, 12,729 in South Florida, 3051 in Washington)—within the 95% CI in all cases.

**Epidemic dynamics with serological shielding.** Next, we retrospectively assess the benefit of a serological shielding strategy implemented in Fall 2020 in each metropolitan area, assuming that test-positive individuals increase their relative rate of interactions, thereby shielding susceptible individuals and reducing the risk of transmission. Specifically, individuals who test positive return to work and increase other contacts to normal levels. We assume that test-negative and untested individuals continue to work from home if their job allows them to do so. To reflect the placement of test-positive individuals in high-contact roles, we assume that contacts at work and other (non-home, non-school) locations are preferentially with test-positive persons. When shielding interactions are 5:1 relative to that of those under social distancing guidelines, the probability of interacting with a test-positive individual is five times what would be expected given the frequency of test-positive individuals in the population, following the model of fixed shielding described in10. In each site, monthly serological testing of the population leads to a flattened epidemic curve in the fall and winter of 2020–2021. Widespread serological testing combined with moderate serologically-informed shielding (5:1) starting on November 1, 2020, using a highly specific test, could have reduced cumulative deaths by June 2021 by 22% across the three sites combined. The strongest reductions are in Washington (59%, 95% CrI for deaths averted: 0–17,000), with a lower relative impact in New York City (8%, 95% CrI for deaths averted: 300–600) and South Florida (14%, 95% CrI for deaths averted: 900–1300) (Fig. 4, top row).

**Impacts of serological testing frequency on epidemic outcomes and release from social distancing.** Simulations of test-based interventions reveal that the magnitude of the benefit from serological shielding depends on the frequency of testing, with more frequent testing resulting in both larger reductions in deaths and in a greater proportion of the population being released from social distancing if a highly specific test is used (Fig. 4, bottom row). In New York, monthly population testing would have been needed to maximize the potential benefit, leading to 51% of the population being released from social distancing by June 1, 2021 (95% CrI: 27–70%) and deaths being reduced by 3000 (95% CrI for total deaths: 20,000–63,000). In contrast, annual population...
testing would have been expected to release 26% of the population from social distancing (95% CrI: 13–37%) with 1500 deaths averted (95% CrI for total deaths: 20,000–64,000). More frequent testing would have also been beneficial in Washington; monthly testing would have released 21% of the population from social distancing (95% CrI: 3–33%) with 11,000 deaths averted (95% CrI for total deaths: 1000–15,000), compared with only 14% released (95% CrI: 1–22%) and 4000 deaths averted (95% CrI for total deaths: 1000–26,000) with annual testing. In South Florida, 41% (95% CrI: 24–61%) of the population would have been released from social distancing with monthly testing, compared with 21% (95% CrI: 12–32%) with yearly testing. Monthly testing would have averted 1500 deaths in South Florida (95% CrI for deaths: 5000–15,000), whereas annual testing would have averted 500

**Fig. 2** The first row shows the consistency between the fitted model and the deaths/seroprevalence data for New York City, South Florida, and Washington Puget Sound. Daily critical care cases through July 1. The second row shows the cumulative number of recovered (previously infected) individuals. Red squares show the seroprevalence estimates from Havers et al. in each location. In the third row, the cumulative deaths are shown, with death data shown in blue squares. Data are presented as mean (black line) ±1.96 sd (gray bands), calculated from 100 random samples. Gray bands show 95% credible intervals, derived from the last 5000 iterations of converged MCMC chains.

**Fig. 3** Critical care cases over time by testing level and location assuming 5:1 shielding. Dates corresponding to the start of general social distancing in March 2020 and lifting at stay-at-home (SAH) orders in May and June 2020, are based on the dates that policies were enacted, or restrictions lifted, in each location. We assume that schools reopened at 50% capacity on September 1, 2020 in South Florida and October 1, 2020 in Washington and New York. Dotted lines show the impacts of a test with 90% specificity and solid lines show a test with 99.8% specificity. The 99.8% specificity scenario represents the accuracy reported among antibody tests currently authorized for use in the U.S., whereas the 90% specificity scenario is meant to capture reductions in accuracy that might be expected in a mass testing program.
deaths (95% CrI for deaths: 6000–16,000). While increasing the intensity of social distancing toward the level of restrictions observed in April 2020 could help reduce deaths, these same benefits could be achieved by adding serological testing as part of a control strategy, allowing social distancing to be safely relaxed. As social distancing measures are relaxed further, testing frequency should also increase to minimize deaths and maximize the proportion of the population that can be released (Fig. 5). The extent to which testing frequency must increase to compensate for relaxing social distancing varies by location. For example, in New York City and South Florida, distancing could have been relaxed fully if monthly testing was employed.

Impacts of serological testing performance and shielding on epidemic outcomes and release from social distancing. The value and safety of a serological testing strategy depend on the level of shielding and test specificity. Thus far, our results centered on dynamics enabled by a high-performance test with a specificity of 99.8%, consistent with the high end of the range of reported specificity of available antibody tests21. We also explored the impact of employing a suboptimal test with 90% specificity, consistent with the lower range of approved tests plus additional decreases in accuracy due to rolling out testing at mass scale. Under this scenario, cumulative deaths across the three locations (66,000) would have been lower than if no-testing strategy was implemented (72,000) but higher than if using a high-performance test (56,000), with 93–99% of the population released from social distancing (New York: 99%, 95% CrI: 95–99%; South Florida: 98%, 95% CrI: 97–100%; Washington: 93%, 95% CrI: 73–97%). However, if monthly testing with a suboptimal assay (90% specificity) was implemented without shielding, 97–99% of the population would have been released from social distancing (99% in New York City, 95% CrI: 95–99%; 98% in South Florida, 95% CrI: 97–100%; and 97% in Washington, 95% CrI: 73–99%) and 78,000 deaths would be expected, more than if no testing were implemented. Overall, adding shielding to a monthly testing strategy results in 10–27% fewer deaths compared to testing at the same frequency without shielding (10% in New York; 14% in South Florida; 27% in Washington). We also set test specificity to 50% to represent a scenario in which antibodies are not a reliable correlate of immunity (i.e., the test is poor at distinguishing between immune and non-immune individuals). If antibodies are not a reliable correlate of protection (which would be counter to current evidence that shows neutralizing antibodies persist for months25), then serological testing could lead to more deaths than if not used at all (Fig. 4, top panel). We conclude that shielding strategies avert deaths with any level of social distancing even when using a moderately specific test (90%) so long as antibodies provide a reasonably good correlate of protection (Fig. 5).

As a sensitivity analysis, we also explored how uncertainty in the natural history parameters (latency period, relative transmissibility of asymptomatic infections, hospital length of stay, and duration of symptomatic and asymptomatic infection) altered the impact of testing and shielding. In general, if asymptomatic cases are more able to transmit than we have assumed in our main model, the impact of shielding would be enhanced. In contrast, faster recovery rates for both symptomatic and asymptomatic cases could decrease the ultimate impact of shielding, particularly in South Florida and Washington, where the initial epidemic wave was relatively mild. Changing the latent period and the duration of hospitalization had minimal impact on the results (Supplementary Figs. 12–14).
Fig. 5 Cumulative deaths and number released from distancing by testing level and contact reductions. Contour plot of cumulative deaths in each location from November 1, 2020 to June 1, 2021 (left column) and the number of people released from social distancing (right column) as a function of the degree of relaxation of social distancing and number of tests per day. The far right of the x-axis corresponds to a pre-pandemic level of contact and the far left corresponds to the contact levels in each location during stay-at-home orders in March–June 2020. Both panels assume a test specificity of 99.8% and a shielding factor of 5:1.
Discussion

After achieving reasonably good fits of the model to historical data, our simulation study reveals that sufficiently frequent testing using high-performance tests combined with serological shielding in the pre-vaccine era would have decreased deaths and allowed relaxed social distancing for a substantial fraction of the population. First, we found that maintaining moderate social distancing equivalent to levels in Fall 2021, together with monthly serological testing, could have relieved 21–51% of several U.S. metropolitan populations from social distancing by June 2021. Second, if moderate shielding was employed, a strategy with serological testing would have resulted in up to 16,000 fewer deaths than a strategy without testing in the three focal areas. Adding shielding alongside monthly testing could have further reduced mortality rates and allowed a substantial fraction of the population to return to work and other activities with relative safety without the social and economic costs of strict, prolonged social distancing measures. Third, we find that such a strategy could in fact prove dangerous, resulting in more deaths, if the serology test is non-specific or if antibodies are not a reliable indicator of immunity. Vaccine passports are already in place in some countries to identify individuals with immunity due to vaccination or recent history of infection. While our models were fit to data before COVID-19 vaccines were widely available, the principle of serological shielding may still prove useful. For example, serological testing could be used to complement vaccination status, identifying more individuals with immunity for whom social distancing could be more safely relaxed.

An aggressive, monthly testing approach is unprecedented but, we argue, may be feasible and warranted under certain scenarios considering the continued social and economic impact of the epidemic. Implementation would require a significant and rapid scale-up of serological testing capacity. In the U.S., this scale-up was achieved for diagnostic PCR testing; the U.S. expanded testing from fewer than 1000 tests per day in early March to nearly 250,000 tests per day in mid-May and about 1 million per day by September. Moreover, recently developed serological tests are quicker to perform than RT-PCR. New York City reported performing a peak of 187,000 tests per week in late March 2020, which corresponds to a rate between the yearly testing and 10% per year testing scenarios we consider in our analysis and could likely be increased with a concerted focus on antibody testing. Highly specific, self-administered bloodspot assays, as well as saliva-based tests, could ease some of the logistical challenges of large-scale testing.

Still, there is a legitimate concern that serological tests to relax social distancing could increase population risk. To the contrary, we show that coupling serological testing using available diagnostic tests with immune shielding can form the basis of a successful risk mitigation strategy. If testing employs the most specific assays available, the false positive proportion would remain low and decrease over time as seroprevalence increases. If test specificity is closer to 90%, the false positive rate could have reached 50% in all sites while remaining lower than the prevalence of positives in the untested population. As such, deploying immune individuals such that they are responsible for more interactions than susceptible individuals will reduce risk. If shielding is not employed, this benefit disappears, and testing can become a liability—reinforcing the critical need to combine serological testing with a shielding strategy. Importantly, false positives are unlikely to substantively impact population-level risk at levels of specificity reported by most authorized serological tests.

In this modeling study, there are a number of assumptions and limitations that should be considered. First, while the credible intervals of cumulative mortality from our models overlap with realized outcomes, there remains considerable uncertainty regarding the extent to which individuals continued to practice social distancing through mid-2021, which is a key parameter in our models. This underscores the challenges of predicting the trajectory of the epidemic amidst uncertainty about shifting behavioral patterns. Social distancing was broadly adopted in the initial response in the United States but quantifying ever-changing patterns of social mixing is challenging and little empirical data on behavioral patterns starting in March 2020 is available. Nevertheless, modeling the impact of changing contact patterns on disease transmission is a critical aspect of our model.

Second, our models assumed random allocation of serological testing. In practice, targeting testing to specific groups, such as healthcare workers, nursing home care providers, food service employees, or contacts of confirmed or suspected cases might increase efficiency by increasing the test-positive rate (and consequently, cost-effectiveness), allowing for similar numbers of individuals to be released from social distancing at lower testing levels. This strategy would also decrease the false positive rate, an important consideration if a less specific test is used. Many healthcare organizations have already begun to offer antibody testing to their employees. The use of serological testing and shielding within healthcare settings represents a smaller-scale, more targeted application of a testing and shielding strategy.

Third, we have made three critical simplifying assumptions in our model. We assume that antibodies are immediately detectable after resolution of infection. In reality, this generally occurs between 11 and 14 days post infection. A small fraction of recent infections would be undetected, but this would likely have a minor effect on our results. Next, we assume that immunity lasts for the duration of our simulations, or at least 15 months. Both the duration of antibody protection and the extent to which those antibodies protect against future infections remains unclear. However, the vast majority of individuals who are infected seroconvert, and ongoing studies of SARS-CoV-2 show that antibodies persist for at least months. Even as antibodies wane, this does not necessarily imply the loss of immune protection. Ongoing studies are needed to determine whether these same patterns hold true for newly emerging variants. In addition, we assume that antibodies detected by serology are a correlate of protection. While antibody levels have been shown to wane after several months, especially for individuals with mild infection, protection following natural infection remains substantial, even when antibodies may be undetectable. Finally, we assume that serology data from Havers et al. are representative of the metropolitan areas in which the studies were conducted. In reality, convenience sampling was used in each location, taking advantage of medical visits for other reasons. While these numbers might be biased, the direction of this potential bias is unclear and Havers et al. remains the best serological data available at the time of writing. We also assume that the age-specific case fatality rates are constant over time. If the actual fatality rate declines over time, this may have led us to overestimate the number of deaths.

Even if testing can be scaled up, legal and ethical concerns remain. Requiring evidence of a positive test to return to activities may create strong incentives for individuals to misrepresent their immune status or intentionally infect themselves. However, this is less of a concern amid the widespread availability of vaccines. Nonetheless, a mass testing program must consider how such policies might enforce existing social disparities and guard against inequities in test availability. Moreover, attention must be paid to the potential risk posed by re-infection, which is especially of concern with new variants.

We have focused our analysis on serological testing, using the principles of serological shielding to reduce risk of infection for
susceptible individuals, but this principle also applies to vaccination48. As of July 2021, three vaccines against SARS-CoV-2 are widely available throughout the United States49, and over 68% of U.S. adults have received at least one dose of vaccine. However, vaccination uptake varies geographically. In the United States, if a rebound in transmission occurs among unvaccinated individuals as variants of concern begin to become more widespread, vaccinated individuals and/or seropositive individuals could also be preferentially placed in high-contact positions to serve as immune “shields”. This could allow transmission to be more controlled, even as social distancing interventions continue to be relaxed. If a novel strain emerges that escapes vaccine-derived and natural immunity, additional testing could identify individuals who have immunity against the escape variant for shielding to be a viable strategy. This strategy might be particularly beneficial in high-risk settings, such as healthcare or long-term care facilities.

A serological testing strategy could be one component of the continued public health response to COVID-19, alongside vaccination, viral testing, masking and contact tracing. Our results show that serological testing coupled with shielding could have mitigated the impacts of the COVID-19 pandemic while also allowing a substantial number of individuals to safely return to social interactions and economic activity, suggesting a future role for serological testing in the ongoing public health response to COVID-19 amid low vaccination coverage and the continuing threat of emergent SARS-CoV-2 variants.

Methods

We modeled the transmission dynamics of SARS-CoV-2 using a deterministic, compartmental SEIR-like model (Fig. 1). We assume that after a latent period, infected individuals progress to either asymptomatic or symptomatic infection. A fraction of symptomatic cases are hospitalized, with a subset of those requiring critical care. Surviving cases, both asymptomatic and symptomatic, recover and are assumed to be immune to re-infection. All individuals who have not tested positive and are not currently experiencing symptoms of respiratory illness are eligible to be tested and all hospitalizations are tested prior to discharge. Recovered individuals are moved to the test-positive group at a rate that is a function of test sensitivity. Susceptible, latentely infected, and asymptomatic cases may falsely test positive and are moved to the test-positive group at a rate that is a function of test specificity. False positives may become infected, but the inaccuracy of their test result is not accounted for in our model. We assumed that after a latent period, children and young adults had a critical illness rate 10-fold lower than adults (compared to symptomatic infection) from 25 to 100%63–65.

To capture the potential influence of uncertainty in fixed parameters on the impact of shielding, we used Latin Hypercube Sampling to generate 300 random parameter sets based on probable ranges for each parameter, assuming a uniform distribution within each range66. We varied the duration of the latent period from 3 to 12 days67,68, the relative transmissibility of asymptomatic infection (compared to symptomatic infection) from 25 to 10069,70, the recovery for non-hospitalized, symptomatic cases from 1 to 10 days71,72 and for asymptomatic cases from 3 to 8 days73,74, and the length of hospitalization from for severe cases from 6 to 20 days and for non-severe cases from 3 to 9 days75,76. We sampled COVID-19 cases from each location, resulting in random parameter sets for each site. We simulated the epidemic forward using each parameter set for the key testing and shielding interventions we report in the text. We report the middle 95% of the distribution of outcomes from these runs as our credible intervals. As only the fitted parameters were varied, the resulting uncertainty intervals only capture uncertainty in the fitted parameters and not in parameters that were fixed from prior literature. If all parameters had been varied, our credible intervals would likely have been wider. We have uploaded a supplementary file with the number of deaths, critical care cases, cumulative incidence, and the fraction of the population released from social distancing after one year from each of these simulations as Supplementary Material. More details regarding model fitting are shown in SI Appendix. S3.

Sensitivity analysis of fixed parameters using partial-rank correlation coefficients

To capture the potential influence of uncertainty in fixed parameters on the impact of shielding, we used Latin Hypercube Sampling to generate 300 random parameter sets based on probable ranges for each parameter, assuming a uniform distribution within each range66. We varied the duration of the latent period from 3 to 12 days67,68, the relative transmissibility of asymptomatic infection (compared to symptomatic infection) from 25 to 10069,70, the recovery for non-hospitalized, symptomatic cases from 1 to 10 days71,72 and for asymptomatic cases from 3 to 8 days73,74, and the length of hospitalization from for severe cases from 6 to 20 days and for non-severe cases from 3 to 9 days75,76. We sampled COVID-19 cases from each location, resulting in random parameter sets for each site. We simulated the epidemic forward using each parameter set for the key testing and shielding interventions we report in the text. We report the middle 95% of the distribution of outcomes from these runs as our credible intervals. As only the fitted parameters were varied, the resulting uncertainty intervals only capture uncertainty in the fitted parameters and not in parameters that were fixed from prior literature. If all parameters had been varied, our credible intervals would likely have been wider. We have uploaded a supplementary file with the number of deaths, critical care cases, cumulative incidence, and the fraction of the population released from social distancing after one year from each of these simulations as Supplementary Material. More details regarding model fitting are shown in SI Appendix. S3.
simulation run with that parameter value. This provides a measure of the effect of the value of each fixed parameter on the impact of shielding in our models.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability.** Death data used for model calibration are available from https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/ and policy data that was used to define the reopening policies by the site are available at https://github.com/nytimes/covid-19-data. Seroprevalence data was previously published by Havers et al. All data used directly in model fitting are available in the Github repository, specifically at https://github.com/lopmanlab/Serological_Shielding/MCMC_CODE/Math/INPUTS.

**Code availability.** Code is available at https://github.com/lopmanlab/Serological_Shielding.

Received: 21 December 2020; Accepted: 19 October 2021; Published online: 03 December 2021

**References.**

1. COVID-19 Map [Internet]. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html. Accessed 12 Nov 2020.
2. Aylin, W. H. S. About 95% of Americans have been ordered to stay at home. This map shows which cities and states are under lockdown [Internet]. Business Insider. https://www.businessinsider.com/us-map-stay-at-home-orders-lockdowns-2020-3. Accessed 16 Apr 2020.
3. Kaplan, J., Frias, L. & Morgan, M.-F. A third of the global population is on coronavirus lockdown—here’s our constantly updated list of countries and restrictions [Internet]. Business Insider. https://www.businessinsider.com/companies-on-lockdown-coronavirus-italy-2020-3. Accessed 20 Apr 2020.
4. American Enterprise Institute - AEI. National coronavirus response: a road map to reopening [Internet]. https://www.aei.org/research-products/report/national-coronavirus-response-a-road-map-to-reopening/. Accessed 14 Apr 2020.
5. Li, Y. et al. The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-COV-2: a modelling study across 131 countries. Lancet Infect. Dis. 21, 193–202 (2021).
6. Walenksy, R. P., Walke, H. T. & Fauci, A. S. SARS-CoV-2 variants of concern persist for months. Science 370, 1227–1230 (2020).
7. Kisler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H. & Lipsitch, M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 368, 860–868 (2020).
8. CDC. COVID data tracker [Internet]. Centers for Disease Control and Prevention. https://covid.cdc.gov/covid-data-tracker/. Accessed 22 July 2021 (2020).
9. Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409–424 (2021).
10. Li, G., Shvaim, S., Hochberg, M. E., Wardi, Y. & Weitz, J. S. Disease-dependent interaction policies to support health and economic outcomes during the COVID-19 epidemic. Science [Internet]. https://www.cell.com/science/abstract/S0036-8074-0042(21)00678-7. Accessed 30 Aug 2021 (2021).
11. Weitz, J. S. et al. Modeling shield immunity to reduce COVID-19 epidemic spread. Nat. Med. 26, 849–854 (2020).
12. COVID-19 vaccine market dashboard [Internet]. https://www.unicef.org/supply/covid-19-vaccine-market-dashboard. Accessed 23 July 2021.
13. Li, R. et al. Robust neutralizing antibodies to SARS-CoV-2 infection learned? Int. J. Epidemiol. 49, 717–726 (2021).
14. Lasserre, R. et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. Preprint at medRxiv https://doi.org/10.1101/2020.04.09.20056325 (2020).
15. Lai, Y. et al. Substantial undocumented infection facilitates the rapid dissemination of SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective study. Clin. Infect. Dis. 71, 2027–2034 (2020).
16. Iyer, A. S. et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. Preprint at medRxiv https://doi.org/10.1101/2020.07.18.20155574 (2020).
17. Baranuki, C. Covid-19: How effective are vaccines against the delta variant? BMJ 374, n1960 (2021).
18. U.S. Food and Drug Administration. EUA authorized serology test performance. FDA [Internet]. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance. Accessed 29 Oct 2020 (2020).
19. Adams, E. R. et al. Antibody testing for COVID-19: a report from the National COVId Scientific Advisory Panel. Wellcome Open Res. 5, 139 (2020).
20. Kaplan, J., Frias, L. & Morgan, M.-F. A third of the global population is on coronavirus lockdown—here’s our constantly updated list of countries and restrictions [Internet]. Business Insider. https://www.businessinsider.com/companies-on-lockdown-coronavirus-italy-2020-3. Accessed 20 Apr 2020.
21. Li, R. et al. Substantial undocumented infection facilitates the rapid dissemination of SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective study. Clin. Infect. Dis. 71, 2027–2034 (2020).
22. Li, R. et al. Robust neutralizing antibodies to SARS-CoV-2 infection learned? Int. J. Epidemiol. 49, 717–726 (2021).
23. Lassaunière, R. et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. Preprint at medRxiv https://doi.org/10.1101/2020.04.09.20056325 (2020).
24. US coronavirus cases and deaths [Internet]. USAFacts.org. https://causesofdeath.vision2019.org/coronavirus-covid-19-spread-map. Accessed 29 Oct 2020 (2020).
25. Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection learned? Int. J. Epidemiol. 49, 717–726 (2021).
26. Roche COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark [Internet]. https://www.roche.com/news/news/world-europe-56522408. Accessed 30 Aug 2021 (2021).
27. Sullivan, P. S. et al. Detection of SARS-CoV-2 RNA and antibodies in diverse samples: protocol to validate the sufficiency of provider-observed, home-collected blood, saliva, and oropharyngeal samples. IMR Public Health Surveill. 6, e19054 (2021).
28. Morley, G. L. et al. Early release - sensitive detection of SARS-COV-2–specific antibodies in dried blood spot samples. Emerg. Infect. Dis. 26, 2970–2973 (2020).
29. Gray, N. et al. Is "no test is better than a bad test"? Impact of diagnostic uncertainty in mass testing on the spread of COVID-19 [Internet]. PLoS ONE 15, e0240775 (2020).
30. Perri, N. C. et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int. J. Epidemiol. 49, 717–726 (2020).
31. Larremore, D. B. et al. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. eLife 10, e64206 (2021).
32. Emory develops diagnostic antibody blood test to determine antibody responses to COVID-19 [Internet]. https://news.emory.edu/stories/2020/04/coronavirus_antibody_blood_test/index.html. Accessed 20 Apr 2020 (2020).
33. Lucia-Sanz, A., Magalíe, A., Rodriguez-Gonzalez, R., Leung, C.-Y. & Weitz, J. S. Modeling shield immunity to reduce COVID-19 transmission in long-term care facilities. Preprint at https://www.medrxiv.org/content/10.1101/2021.07.16.21260657v1 (2021).
34. Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. 71, 2027–2034 (2020).
35. Patel, M. M. et al. Change in antibodies to SARS-CoV-2 over 60 days among health care personnel in Nashville, Tennessee. JAMA 324, 1781–1782 (2020).
36. Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200–1204 (2020).
37. Ibarrongordo, F. J. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild covid-19. N. Engl. J. Med. 383, 1085–1087 (2020).
38. Hall, V. J. et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 397, 1725–1735 (2021).
39. Signorelli, C. & Odome, A. Age-specific COVID-19 case-fatality rate: no evidence of changes over 65. J. Public Health 173, 1435–1436 (2021).
40. Phelan, A. L. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges. Lancet 395, 1595–1598 (2020).
47. Norheim, O. F. Protecting the population with immune individuals. Nat. Med. 26, 823–824 (2020).
48. Considerations and principles for shielding people at high risk of severe outcomes from COVID-19. GOARN [Internet]. https://extranet.who.int/goarn/considerations-and-principles-shielding-people-high-risk-severe-outcomes-covid-19. Accessed 29 Oct 2020.
49. FDA. COVID-19 vaccines. [Internet]. https://www.fda.gov/emergency-preparedness-response/coronavirus-disease-2019-covid-19-vaccines. Accessed 23 July 2021 (2021).
50. Mossong, J. et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5, e74 (2008).
51. Prem, K., Cook, A. R. & Jit, M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput. Biol. 13, 1601726 (2017).
52. Stand up Miami [Internet]. https://www.miamigov.com/Government/Stand-Up-Miami. Accessed 10 Nov 2020.
53. COVID-Amp: analysis and mapping of policies [Internet]. https://www.covid-local.org/ampl/. Accessed 10 Nov 2020.
54. The New York Times. See how all 50 states are reopening (and closing again) [Internet]. https://www.nytimes.com/interactive/2020/us/states-reopen-map-coronavirus.html. Accessed 10 Nov 2020.
55. Feehan, D. M. & Mahmud, A. Quantifying interpersonal contact in the United States during the spread of COVID-19: first results from the Berkeley Interpersonal Contact Study. Nat. Commun. 12, 893 (2021).
56. Hamra, G., MacLehose, R. & Richardson, D. Markov Chain Monte Carlo: an introduction for epidemiologists. Int. J. Epidemiol. 42, 627–634 (2013).
57. O’Neill, P. D. A tutorial introduction to Bayesian inference for stochastic epidemic models using Markov chain Monte Carlo methods. Math. Biosci. 180, 103–114 (2002).
58. Hazzio, H., Laine, M., Mira, A. & Saksman, E. DRAM: efficient adaptive Metropolis-Stat. Comput. 16, 339–354 (2006).
59. Hazzio, H., Saksman, E. & Tamminen, J. An adaptive metropolis algorithm. Bernoulli 7, 223–242 (2001).
60. Marino, S., Hogue, I. B., Ray, C. J. & Kirschner, D. E. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theo. Biol. 254, 178–196 (2008).
61. Lauer, S. A. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med. 172, 577–582 (2020).
62. McAloon, C. et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open 10, e039652 (2020).
63. Sayamanpanathan, A. A. et al. Infectivity of asymptomatic versus symptomatic COVID-19. Lancet 397, 93–94 (2021).
64. Zhou, R. et al. Viral dynamics in asymptomatic patients with COVID-19. Int. J. Infect. Dis. 96, 288–290 (2020).
65. Zou, L. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 382, 1177–1179 (2020).
66. Lee, S. et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. JAMA Intern. Med. 180, 1447 (2020).
67. Faes, C. et al. Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients. Int. J. Environ. Res. Public Health 17, 7560 (2020).
68. CDC. COVID-19 and your health [Internet]. https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html. Accessed 23 July 2021 (2020).
69. Byrne, W. et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open 10, e039856 (2020).
70. Bregman, H. & Gallagher, K. Inpatient lengths of stay, number of ICU days among COVID-19 patients differ from common model assumptions [Internet]. Epic Health Research Network. https://ehrn.org/articles/inpatient-lengths-of-stay-and-number-of-icu-days-among-covid-19-patients-differ-from-common-model-assumptions/. Accessed 23 July 2021.